Express Pharma

Axol Bioscience to launch Novel iPSC-derived cells at ISSCR 2016


The human cell culture specialists will showcase innovative tools and applications for disease modelling and drug discovery

Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. Axol will launch three products at International Society for Stem Cell Research (ISSCR) 2016, to be held in San Francisco, CA from June 22–25, 2016.

The products which will be launched are Human iPSC-Derived Atrial Cardiomyocytes, Human iPSC-Derived Endothelial Colony Forming Cells (ECFCs) and axolGEMs (Genetically Edited Models), Axol’s new range of isogenic human iPSC-derived cells carrying disease-relevant mutations developed in partnership with Horizon Discovery. Axol and its collaborators will also be presenting an Innovation Showcase and posters highlighting the characteristics and functional applications of its human iPSC-derived neural cells and cardiomyocytes.

Comments are closed.